RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

New data presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting offers a potential breakthrough for patients with advanced non-small cell lung cancer (NSCLC) harboring atypical epidermal growth factor receptor (EGFR) mutations. Updated results from the Phase 1/1b CHRYSALIS-2 study indicate that combining the intravenous therapy RYBREVANT (amivantamab-vmjw) with the oral medication LAZCLUZE (lazertinib) resulted in a median overall survival of nearly 3.5 years in this difficult-to-treat patient population.

Addressing a Significant Clinical Gap

Patients with atypical EGFR mutations—which account for approximately 10 to 20 percent of all EGFR-mutated cases—have historically faced poorer outcomes compared to those with common mutations. Current standard-of-care, single-agent therapies often result in a median overall survival of under two years, leaving a substantial unmet need for more durable treatment options.

The study, which evaluated 49 patients in Cohort C, demonstrated that the combination therapy provided consistent clinical activity across various atypical mutation subgroups. Notably, 41 percent of patients remained on the treatment for two years or longer, suggesting that addressing multiple disease drivers simultaneously may offer a more effective strategy than relying on single-pathway inhibitors.

Did You Know? Approximately 35 percent of the patients in the CHRYSALIS-2 study cohort evaluated for atypical EGFR mutations actually harbored multiple atypical mutations, highlighting the molecular complexity often present in this subtype of lung cancer.

Expert Perspectives on Treatment Evolution

Dr. Joel Neal, principal investigator of the CHRYSALIS-2 study and Professor of Medicine in the Division of Oncology at Stanford Medicine, noted that clinical decision-making for these patients has often been hindered by uncertainty regarding the efficacy of existing inhibitors. He suggested that the durable disease control observed in the trial could begin to reshape how clinicians approach the management of this specific subtype of lung cancer.

Johnson & Johnson’s Global Therapeutic Area Head, Oncology, Dr. Yusri Elsayed, emphasized that the results support a shift away from single-pathway strategies. By dual-targeting EGFR and mesenchymal-epithelial transition (MET) while engaging the immune system, the RYBREVANT-based regimen aims to change the underlying biology of the disease from the start of treatment.

Expert Insight: The shift toward dual-targeting agents like RYBREVANT represents a fundamental change in oncology. By addressing both EGFR and MET pathways simultaneously, clinicians are not just treating the tumor, but actively attempting to delay the inevitable development of resistance that plagues single-agent therapies. The stake here is not just about extending survival, but about providing a sustained quality of life in a population that has historically been underserved by standard-of-care options.

Future Implications for Patient Care

As researchers continue to analyse the data, a possible next step may involve integrating these findings into broader clinical practice guidelines to solidify the role of this combination as a preferred first-line option. Given the durability of the response seen in the CHRYSALIS-2 study, it is likely that future clinical investigations will continue to explore how these bispecific antibody-based regimens perform in even more diverse patient populations and tumor types.

What to Look Forward to at ASCO 2026

While the safety profile remained consistent with previous reports—with most adverse events categorized as Grade 1 or 2—clinicians will likely remain focused on monitoring for known side effects such as rash, paronychia, and infusion-related reactions. The continued observation of these patients could provide further clarity on the long-term management of therapy-related side effects in the first-line setting.

Frequently Asked Questions

What is the primary significance of these new results?
The results show that the combination of RYBREVANT and LAZCLUZE achieved a median overall survival of nearly 3.5 years in patients with atypical EGFR-mutated advanced NSCLC, a group that historically has had fewer durable treatment options compared to those with common EGFR mutations.

How does the treatment work?
RYBREVANT is a first-in-class, fully human bispecific antibody designed to dual-target EGFR and MET while engaging the immune system, while LAZCLUZE is an oral, third-generation, brain-penetrant EGFR tyrosine kinase inhibitor.

What were the most common adverse events reported?
The most common treatment-emergent adverse events occurring in more than 30 percent of patients were paronychia (78 percent), rash (65 percent), hypoalbuminemia (61 percent), and infusion-related reactions (61 percent).

How might these findings influence the way oncologists prioritize diagnostic testing for specific EGFR mutations in newly diagnosed lung cancer patients?